Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials

Martin Bergman · Maya H. Buch · Yoshiya Tanaka · Gustavo Citera · Sami Bahlas · Ernest Wong · Yanna Song · Patrick Zueger · Mira Ali · Vibeke Strand

Received: May 12, 2022 / Accepted: August 5, 2022 / Published online: September 20, 2022 © The Author(s) 2022

ABSTRACT

Introduction: The Routine Assessment of Patient Index Data 3 (RAPID3) is a patient-reported outcome tool recommended for the assessment of disease activity in patients with rheumatoid arthritis (RA) in clinical practice. This analysis evaluated the long-term effect of upadacitinib vs. comparators on RAPID3 scores in patients with RA in the phase 3 SELECT clinical trial program.

Methods: This post hoc analysis included data from five randomized controlled trials (RCTs) in patients receiving upadacitinib 15 mg or 30 mg once daily (QD) as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The proportions of patients reporting RAPID3 remission (scores ≤ 3) were assessed at week 60. Correlations between absolute scores for RAPID3 and Clinical Disease Activity Index

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40744-022-00483-4.

M. Bergman (✉) Drexel University College of Medicine, 23 W Chester Pike, Ridley Park, PA 19078, USA e-mail: mjbergman@prodigy.net

M. H. Buch Centre for Musculoskeletal Research, School of Biological Sciences, University of Manchester and NIHR Manchester Biomedical Centre, Manchester, UK

Y. Tanaka University of Occupational and Environmental Health Japan, Kitakyushu, Japan

G. Citera Instituto de Rehabilitación Psicofísica, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

S. Bahlas Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

E. Wong Department of Rheumatology, Queen Alexandra Hospital, Portsmouth, UK

Y. Song · P. Zueger · M. Ali AbbVie Inc., North Chicago, IL, USA

V. Strand Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, USA
(CDAI), Simplified Disease Activity Index (SDAI), and 28-joint Disease Activity Score with C-reactive protein (DAS28[CRP]) at week 60 were assessed using Spearman correlation coefficients.

**Results:** A total of 3117 patients were included from the SELECT-NEXT, -BEYOND, -MONOTHERAPY, -COMPARE, and -EARLY trials. By week 60, 32–52% of methotrexate-naïve and csDMARD inadequate responder (IR) patients treated with either upadacitinib 15 mg QD or upadacitinib 30 mg QD reported RAPID3 scores consistent with remission. The proportions were slightly lower in the biologic DMARD-IR SELECT-BEYOND population (19–28%). RAPID3 scores highly correlated (Spearman correlation values ≥ 0.58) with CDAI, SDAI, and DAS28(CRP) scores through week 60 (all \( p < 0.001 \)).

**Conclusions:** Upadacitinib, as monotherapy or in combination with csDMARDs, was associated with patient-reported remission assessed by RAPID3 over 60 weeks across the SELECT RCTs in patients with RA.

**Trial registration:** SELECT-BEYOND (NCT02706847); SELECT-NEXT (NCT02675426); SELECT-MONOTHERAPY (NCT02706951); SELECT-EARLY (NCT02706873); SELECT-COMPARE (NCT02629159).

**Plain Language Summary**

Rheumatoid arthritis (RA) is a disease that causes inflammation of the joints. Doctors have several ways of assessing how bad a patient’s disease is, and these often use a combination of signs and symptoms to develop a ‘score’. One method is called RAPID3, which is a score based on an overall assessment of the disease by the patient, the level of pain, and the amount of physical disability. An advantage of RAPID3 is that it is quick and easy to use, and since it uses only patient-reported symptoms, it can be measured easily via telemedicine, without the need for an in-person consultation. In this study, we decided to look into the effect of upadacitinib, a drug used for the treatment of RA, on RAPID3 score in patients with RA. We also investigated whether RAPID3 correlates with other ways of measuring RA severity, including scores that use physician-measured factors such as number of affected joints, as this can help show whether RAPID3 is a valid and useful tool. We found that upadacitinib led to long-term improvements in RAPID3 score, and that results were the same in different studies and patient groups, including patients who had not responded well to other treatments. We also found that RAPID3 correlated well with other measures, i.e., improvements in RAPID3 happened in parallel with improvements in other scores. Overall, these results suggest that RAPID3 can be a useful tool in patients with RA.

**Keywords:** RAPID3; Upadacitinib; Rheumatoid arthritis

| Key Summary Points |
|---------------------|
| **Why carry out this study?** |
| RAPID3 is a patient-reported outcome tool that assesses burden of disease in RA; the effect of upadacitinib treatment on RAPID3 has not yet been evaluated. |

| **What was learned from the study?** |
| Upadacitinib, as monotherapy or in combination with csDMARDs, was associated with long-term improvements in RAPID3; results were consistent over different studies and patient populations, including patients more refractory to treatment. |

| RAPID3 showed good correlation with other disease activity measures, supporting its use to assess disease activity and treatment responses across RA patient populations in clinical practice. |
INTRODUCTION

A treat-to-target approach aiming for remission or low disease activity (LDA) is advocated in the management of rheumatoid arthritis (RA) by both the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) [1, 2]. Regular assessment of disease activity during routine care is required when aiming for such targets [1, 2]. There are several disease activity assessments recommended by the ACR, such as the 28-joint Disease Activity Score (DAS28), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), and Routine Assessment of Patient Index Data 3 (RAPID3) [3]. Most assessments include a mixture of physician evaluations, objective markers of inflammation, and patient-reported outcomes (PROs) [3]. However, RAPID3 is based solely on PROs, being a pooled index of Patient’s Global Assessment of Disease Activity (PtGA), pain and physical function (Functional Component of the Health Assessment Questionnaire Disability Index [HAQ-Di]), and multidimensional HAQ (MDHAQ) [4]. Each measure is scored from 0 to 10, providing a total score out of 30: scores >12 indicate high disease activity (HDA), >6–12 moderate disease activity (MDA), >3–6 LDA, and ≤3 remission [5].

RAPID3 is simple and quick to complete by patients and can be performed easily via telemedicine without requiring an in-person consultation with a rheumatologist. It is used alongside other clinical assessments by healthcare providers to evaluate overall disease activity and has shown good-to-excellent correlations with DAS28 using C-reactive protein (DAS28[CRP]) and CDAI/SDAI, with similar sensitivity for distinguishing active and control treatments in randomized controlled trials (RCTs) [5].

Upadacitinib is an oral selective Janus kinase-1 inhibitor indicated for use in moderately to severely active RA [6, 7]. Its efficacy and safety in RA, as monotherapy or in combination with methotrexate or other conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), has been demonstrated in the comprehensive phase 3 program of ‘SELECT’ RCTs across diverse patient populations, including csDMARD-naïve patients, csDMARD inadequate responder (IR) patients, and biologic DMARD (bDMARD) IR patients [8–14]. Integrated safety analyses and long-term extension data of these trials support the durability of upadacitinib efficacy and tolerability over a prolonged period [13, 14]. The objective of the current analysis was to evaluate the impact of upadacitinib vs. comparators using RAPID3 over 60 weeks, as well as to further explore the correlation of RAPID3 scores with other disease measures in the upadacitinib phase 3 SELECT clinical program in RA.

METHODS

Study Design and Patients

This post hoc analysis included data from five randomized controlled phase 3 trials from the upadacitinib RA clinical trial program: SELECT-NEXT [8] and SELECT-BEYOND [9] were placebo controlled, and SELECT-EARLY [10], SELECT-MONOTHERAPY [11], and SELECT-COMPARE [12] all had active comparators (methotrexate, methotrexate, and adalimumab, respectively). Only treatment groups evaluated at 60 weeks with no treatment crossover and reporting RAPID3 data from the trials were included in the analysis. Patient inclusion and exclusion criteria have been published previously [8–12]. In summary, all patients were adults aged ≥18 years with moderately to severely active RA and were a mixture of methotrexate-naïve, methotrexate-IR, csDMARD-IR, or bDMARD-IR patients. Patients received upadacitinib (15 mg or 30 mg once daily [QD]) as monotherapy or in combination with csDMARDs. A summary of the study designs and patient populations of the SELECT trials is shown in Table S1 in the Supplementary Material.
Ethics Declaration

All SELECT trials were conducted according to the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki of 1964 and its later amendments. All patients provided written informed consent. The trial protocols were approved by the relevant independent ethics committees and institutional review boards of all participating institutions, and were sponsored by AbbVie. All authors have provided their approval for this version to be published.

Assessments

RAPID3 scores (consisting of PtGA scores of 0–10 and pain scores of 0–10 [assessed using visual analog scales], plus HAQ-DI scores multiplied by 3.3 [as a substitute for the functional component of the MDHAQ]) [15] were calculated at weeks 12, 24, and 60. The proportions of patients reporting RAPID3 remission, LDA, MDA, and HDA were assessed at week 60, as were the mean changes from baseline in RAPID3 scores. A 3.8-point decrease (improvement) in the RAPID3 score represents the minimal clinically important difference (MCID) [16].

CDAI, SDAI, and DAS28(CRP), swollen and tender joint counts for 28 joints (SJC/TJC28), and high-sensitivity CRP (hsCRP) were also assessed at week 60. CDAI remission was defined as ≤ 2.8; DAS28(CRP) remission as < 2.6; and Boolean remission as TJC ≤ 1, SJC ≤ 1, CRP ≤ 1 mg/dl, and PtGA ≤ 1.

Statistical Analyses

Mean change from baseline in RAPID3 scores and the proportion of patients reporting RAPID3 remission (≤ 3), LDA (> 3 to ≤ 6), MDA (> 6 to ≤ 12), HDA (> 12), and improvements that exceeded the MCID were assessed. Correlations between RAPID3 and CDAI, SDAI, and DAS28(CRP) scores were assessed using Spearman correlation. Correlation coefficients < 0.3 were considered low correlation, 0.3–0.6 moderate correlation, and > 0.6 high correlation. A univariate logistic regression model with CDAI or Boolean remission at week 60 as the dependent variable, and early RAPID3 response as the independent variable, was used to assess the association between clinical remission and early RAPID3 response. Spearman correlations were also calculated between the individual components of RAPID3 and disease outcomes (CDAI, SDAI, DAS28(CRP), TJC28, and SJC28).

RESULTS

Patient Disposition and Baseline Disease Activity

A total of 3117 patients who received active treatment (i.e., excluding placebo-treated patients) were included in the analysis across the five RCTs (440, 324, 431, 978, and 944 patients from SELECT-NEXT, -BEYOND, -MONOTHERAPY, -COMPARE, and -EARLY trials, respectively); 2477 patients received either upadacitinib 15 mg or 30 mg QD.
Supplementary Table S2). Detailed baseline characteristics of patients in each trial have been published previously [8–12] but, in summary, the majority of patients across all studies had RAPID3 HDA at baseline (mean scores: 17.2–19.2) (Supplementary Table S2).

RAPID3 Scores with Upadacitinib Treatment

By week 60, 32–52% of methotrexate-naive and csDMARD-IR patients treated with either upadacitinib 15 mg QD or upadacitinib 30 mg QD were in RAPID3 remission, with slightly lower proportions among bDMARD-IR patients in SELECT-BEYOND (19.4 and 28.1%, respectively) (Fig. 1). When including LDA, this figure increased to 47–70% in methotrexate-naive and csDMARD-IR patients treated with upadacitinib, with again a lower proportion of the more refractory SELECT-BEYOND population reporting remission or LDA (35.8–42.1%) (Fig. 1). In patients receiving methotrexate in SELECT-EARLY, 27.1% reported remission and 43.6% reported remission or LDA at week 60. In patients receiving adalimumab (SELECT-COMPARE), 22.3% of patients reported remission and 33.2% reported remission or LDA (Fig. 1). The percentages of upadacitinib-treated patients reporting RAPID3 remission at weeks 12/14 and weeks 24/26 were 14–33% and 15–40%, respectively, across trials (Fig. 1). With methotrexate (SELECT-EARLY), the percentages were 15.5 and 18.3% at weeks 12 and 26, respectively, and for adalimumab (SELECT-COMPARE), 14.3 and 18.8%, respectively, at weeks 14 and 26 (Fig. 1). Overall, the percentages at weeks 12/14 and 24/26 were maintained or continued to improve through week 60.

The smallest mean (standard deviation) changes from baseline at week 60 in RAPID3 scores were reported in bDMARD-IR patients from SELECT-BEYOND (upadacitinib 15 mg QD – 8.6 [6.8]; upadacitinib 30 mg QD – 9.3 [7.3]), while the largest were in methotrexate-naive patients from SELECT-EARLY (– 12.0 [7.6] and – 13.4 [7.2], respectively). The majority of patients treated with upadacitinib 15 mg QD and upadacitinib 30 mg QD (74–92%) reported improvements from baseline in RAPID3 scores at week 60 that exceeded the MCID (Supplementary Fig. S1). The percentages of methotrexate-treated patients (SELECT-EARLY) and adalimumab-treated patients (SELECT-COMPARE) who reported improvements ≥ MCID were 77 and 77%, respectively (Supplementary Fig. S1).

Correlation Between RAPID3 and Other Disease Activity Measures

Mean RAPID3 scores were highly correlated with mean scores in other disease activity measures, with Spearman correlation values of > 0.6 (except for one value of 0.58) across all trials, patient populations, and treatment arms (upadacitinib and comparators) through week 60 (Fig. 2). Spearman correlation values ranged from 0.69 to 0.83 for CDAI, 0.69–0.82 for SDAI, and 0.58–0.77 for DAS28(CRP) (p < 0.001 for all correlations).

Scores for components of the composite measures of disease activity, including SJC28, TJC28, hsCRP, Physician’s Global Assessment of Disease Activity, and PtGA, were consistently lower in patients who reported RAPID3 remission compared with those not in remission at week 60 (Fig. 3). Similar trends were evident when comparing components of disease activity in patients in RAPID3 LDA compared with those who were not (data not shown).

At week 60, there were moderate-to-high agreements between RAPID3 remission in the
upadacitinib 15 mg QD and 30 mg QD treatment groups and remission defined by CDAI (range of kappa scores, 0.52–0.67), SDAI (0.51–0.68), DAS28(CRP) (0.35–0.47), and Boolean remission (0.53–0.72) using NRI (\(p < 0.001\) for all correlations; Supplementary Table S3). Similar results were evident with as-observed data: CDAI kappa scores 0.47–0.62, SDAI kappa scores 0.47–0.61, DAS28(CRP) kappa scores 0.30–0.47, and Boolean remission kappa scores 0.53–0.72 (\(p < 0.001\) for all kappa scores).

Univariate logistic regression analyses showed associations between early RAPID3 scores, including change from baseline and reporting of remission/LDA at weeks 12/14, and CDAI or Boolean remission at week 60, as demonstrated by both odds ratios (Supplementary Table S4A) and C-indices (Supplementary Table S4B).

PtGA, pain, and HAQ-DI individually correlated less closely with CDAI, SDAI, and DAS28(CRP) at week 60 than the composite RAPID3 score (Supplementary Table S5). Conversely, PtGA and pain showed a higher correlation with CDAI, SDAI, and DAS28(CRP) than RAPID3 score.

**DISCUSSION**

This analysis showed that upadacitinib, as monotherapy or in combination with csDMARDs, was associated with long-term improvements in physical function, PtGA, and pain, as measured by RAPID3, over 60 weeks in the phase 3 SELECT RA clinical program. The results were consistent over different studies and patient populations, even in those considered more refractory to treatment. Generally, greater proportions of patients treated with upadacitinib 30 mg QD reported RAPID3 remission compared with upadacitinib 15 mg QD, with maintained improvement in the percentages in remission in both treatment groups from week 12 through to week 60. Similar PRO improvements (at 12 or 14 weeks) with upadacitinib 15 mg or 30 mg QD across the individual trials of the SELECT clinical trial program were reported [18–21], and the present analysis extends these previous assessments of PROs with upadacitinib treatment.

Moderate-to-high correlations seen between RAPID3 scores and other disease activity measures in this analysis are in line with similar associations reported in other analyses from both RCTs and observational data [5, 22–25]. It should be noted that these correlations extended beyond the initial double-blind periods of the SELECT trials into the open-label phases up to 60 weeks. Composite RAPID3 scores correlated more closely with TJC28 and SJC28 than any of the individual components, suggesting that RAPID3 offers some advantages vs. its components in assessing joint symptoms. PtGA showed a higher correlation with CDAI, SDAI, and DAS28(CRP) than overall RAPID3 score; this is not unexpected, as PtGA is a component of CDAI/SDAI/DAS28(CRP) and therefore likely to show a strong correlation with the composite scores. These observations support the use of RAPID3 in clinical practice to assess disease activity in RA alongside other physician-reported and objective measures of disease.

RAPID3 can quickly and easily be calculated from the MDHAQ [26, 27]. In the present analyses we used HAQ-DI for the functional component, as in several previous studies.
For example, a post hoc analysis was carried out of long-term (24-month) RAPID3 data in two phase 3 RCTs in methotrexate-naive or methotrexate-IR patients with RA receiving the Janus kinase inhibitor tofacitinib as monotherapy or with background methotrexate [29]. Results were similar to the current analysis: most patients reported maintained RAPID3 responses from baseline to 24 months with tofacitinib treatment, and RAPID3 remission or LDA at 6 months was associated with better treatment outcomes at month 24.

This analysis has several limitations. It was conducted post hoc and the statistical assessment did not control for multiple comparisons. Furthermore, not all SELECT trials were included in the analysis; SELECT-CHOICE [31] was not included as it did not assess RAPID3 and there are no long-term data currently available. While one of the strengths of this analysis results from the data being collected in a rigorous manner as part of a series of RCTs, this also means that the outcomes may not be generalizable to a wider patient population. Consequently, future analyses from real-world studies or observational data may be valuable to confirm the performance of RAPID3 disease assessment for upadacitinib-treated patients in routine clinical practice.

CONCLUSIONS

This post hoc analysis has shown that treatment with upadacitinib, as monotherapy or in combination with csDMARDs, was associated with improvements in RAPID3 (PtGA, pain, and physical function) over 60 weeks across five RCTs in the SELECT phase 3 clinical program in patients with RA. RAPID3 correlated highly with other disease activity measures, supporting its use to assess disease activity and treatment responses across RA patient populations in clinical practice as a simple and quick PRO.

ACKNOWLEDGMENTS

Funding. AbbVie Inc. (North Chicago, IL, USA) funded this study and the journal’s Rapid Service Fee and Open-Access Fee, and participated in the study design, research, analysis, data collection, interpretation of data, review, and approval of the publication.

Medical Writing, Editorial, and Other Assistance. Medical writing support was provided by Dan Booth, PhD, on behalf of 2 the Nth (Cheshire, UK), and was funded by AbbVie.

Authorship. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Authorship Contributions. Martin Bergman, Maya H. Buch, Yoshiya Tanaka, Gustavo Citera, Sami Bahlas, Ernest Wong, Yanna Song, Patrick Zueger, Mira Ali, and Vibeke Strand were all involved in study conception and design, data collection, analysis and interpretation, drafting the manuscript and revising it for critically important intellectual content, and approving the final version.

Disclosures. Martin Bergman has received consulting fees from AbbVie, Amgen, GSK, Janssen, Novartis, Pfizer, Sanofi, and Scipher; speaking fees from AbbVie, Amgen, GSK, Novartis, and Sanofi; and is a shareholder of Johnson & Johnson and Merck. Maya H. Buch has received research grants from Pfizer, Roche, and UCB; and consulting fees from AbbVie, Eli Lilly, Merck Serono, Pfizer, Sandoz, and Sanofi. She is supported by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre, and has been awarded NIHR Senior Investigator Status. Yoshiya Tanaka declares speaking fees and/or honoraria from AbbVie, Asahi Kasei, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, GSK, Janssen, Mitsubishi Tanabe, Novartis, Pfizer, Sanofi, Takeda, UCB, and YL Biologics; and

△ Adis
research grants from AbbVie, Astellas, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Mitsubishi Tanabe, MSD, Ono, Taisho Toyama, and Takeda. Gustavo Citera has received consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Genzyme, Pfizer, and Roche. Sami Bahlas declares no conflicts of interest. Ernest Wong has received research grants from AbbVie, Chugai, Novartis, and UCB; and consulting fees from AbbVie, Chugai, Eli Lilly, MSD, Novartis, Pfizer, Roche, and UCB. Yanna Song, Patrick Zueger, and Mira Ali are employees of AbbVie and may own stock or options. Vibeke Strand declares consulting fees from AbbVie, Amgen, Arena, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Celltrion, Eli Lilly, Gilead, Ichnios, Inmedix, Janssen, Kiniksa, MSD, Novartis, Pfizer, Regeneron, Rheos, Samsung, Sandoz, Sanofi, Scipher, Set-point, Spheron, and UCB.

**Compliance with Ethics Guidelines.** All SELECT trials were conducted according to the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki of 1964 and its later amendments. All patients provided written informed consent. The trial protocols were approved by the relevant independent ethics committees and institutional review boards of all participating institutions, and were sponsored by AbbVie. All authors have provided their approval for this version to be published. The study reports a post hoc analysis of data from five previously published clinical trials. Ethics approval was obtained for each of those trials, and is reported in the published papers.

**Data Availability.** AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual, and trial-level data (analysis datasets), as well as other information (e.g., protocols and clinical study reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. These clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan, and execution of a Data Sharing Agreement. Data requests can be submitted at any time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit a request, visit https://www.abbvie.com/our-science/clinical-trials/clinical-trials-data-and-information-sharing/data-and-information-sharing-with-qualified-researchers.html.

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

**REFERENCES**

1.Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021;73:924–39.

2. Smolen JS, Landewe RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685–99.

3. England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity.
measures. Arthritis Care Res (Hoboken). 2019;71:1540–55.

4. Pincus T, Strand V, Koch G, et al. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial. Arthritis Rheum. 2003;48:625–30.

5. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35:773–8.

6. AbbVie. Rinvoq. Prescribing information. 2022. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. Accessed 21 July 2022.

7. AbbVie. Rinvoq. Summary of product characteristics. 2022. https://www.ema.europa.eu/en/documents/product-information/rinvoq-epar-product-information_en.pdf. Accessed 21 July 2022.

8. Burmester GR, Kremer JM, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomized, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503–12.

9. Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513–24.

10. van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately to severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607–20.

11. Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303–11.

12. Fleischmann R, Pangan AL, Song I-H, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788–800.

13. Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:779–87.

14. Conaghan PG, Mysler E, Tanaka Y, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44:515–30.

15. Pincus T, Yazici Y, Bergman M. Development of a multi-dimensional health assessment questionnaire (MDHAQ) for the infrastructure of standard clinical care. Clin Exp Rheumatol. 2005;23:519–28.

16. Ward MM, Castrejon I, Bergman MJ, et al. Minimal clinically important improvement of routine assessment of patient index data 3 in rheumatoid arthritis. J Rheumatol. 2019;46:27–30.

17. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22:776–82.

18. Strand V, Schiff M, Tundia N, et al. Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2019;21:263.

19. Strand V, Pope J, Tundia N, et al. Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: results from SELECT-NEXT. Arthritis Res Ther. 2019;21:272.

20. Strand V, Tundia N, Bergman M, et al. Upadacitinib improves patient-reported outcomes vs placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. Rheumatology (Oxford). 2021;60:5583–94.

21. Strand V, Tundia N, Wells A, et al. Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. Rheumatology (Oxford). 2021;60:3209–21.

22. Pincus T, Furer V, Keystone E, et al. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol. Arthritis Care Res (Hoboken). 2011;63:1142–9.
23. Singh H, Gupta V, Ray S, et al. Evaluation of disease activity in rheumatoid arthritis by Routine Assessment of Patient Index Data 3 (RAPID3) and its correlation to Disease Activity Score 28 (DAS28) and Clinical Disease Activity Index (CDAI): an Indian experience. Clin Rheumatol. 2012;31:1663–9.

24. Che H, Combe B, Morel J, et al. Performance of patient-reported outcomes in the assessment of rheumatoid arthritis disease activity: the experience of the ESPOIR cohort. Clin Exp Rheumatol. 2016;34:646–54.

25. Munoz JGB, Giraldo RB, Santos AM, et al. Correlation between rapid-3, DAS28, CDAI and SDAI as a measure of disease activity in a cohort of Colombian patients with rheumatoid arthritis. Clin Rheumatol. 2017;36:1143–8.

26. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10–20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. Best Pract Res Clin Rheumatol. 2007;21:755–87.

27. Yazici Y, Bergman M, Pincus T. Time to score quantitative rheumatoid arthritis measures: 28-Joint Count, Disease Activity Score, Health Assessment Questionnaire (HAQ), Multidimensional HAQ (MDHAQ), and Routine Assessment of Patient Index Data (RAPID) scores. J Rheumatol. 2008;35:603–9.

28. Khawaja MN, Bergman M, Yourish J, et al. Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism provisional remission definitions as predictors of radiographic outcome in a rheumatoid arthritis clinical trial with tocilizumab. Arthritis Care Res (Hoboken). 2017;69:609–15.

29. Strand V, Lee EB, Yazici Y, et al. Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. Clin Rheumatol. 2018;37:2043–53.

30. Qorolli M, Rexhepi B, Rexhepi S, et al. Association between disease activity measured by RAPID3 and health-related quality of life in patients with rheumatoid arthritis. Rheumatol Int. 2019;39:827–34.

31. Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020;383:1511–21.